GoldenGolden
Capricor Therapeutics

Capricor Therapeutics

Capricor Therapeutics is a biotechnology company developing biological treatments for rare health disorders.

Capricor Therapeutics is a biotechnology company that is interested in developing and commercializing cell and exosome-based therapeutics for the purpose of treating and preventing diseases. The company was founded in 2005 in Los Angeles, California, United States.

The company has developed an allogenic cell therapy that is meant to treat Duchenne muscular dystrophy as well as COVID-19. They have been developing extracellular vesicles and are researching potential exosome-based candidates for treating a variety of disorders.

Capricor Therapeutics' lead candidate for treatments is the CAP-1002. It works as a cardiac cell therapy that directly treats Duchenne muscular dystrophy and COVID-19. It consists of cardiosphere-derived cells (CDCs) and a population of cells that exert immunomodulatory activity to alter an immune system's activity, stimulating cellular regeneration.

The company investigates exosome science and biologically-active contents secreted by cells. They look to serve both direct and re-direct activities that serve other cells.

Timeline

December 18, 2010
Capricor Therapeutics raises a $2,000,000 series A round from Broadview Ventures.
2005
Capricor Therapeutics was founded.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

Capricor Therapeutics working on drug to treat a rare disorder DMD

September 18, 2018

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 18, 2021
BioSpace
Capricor Therapeutics, a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced that the Company will present data supporting its Exosome-Mediated mRNA Delivery approach against SARS-CoV-2 at the 10th Annual Meeting of the International Society for Extracellular Vesicles, which is being held virtually May 18-21, 2021.
BioSpace
November 24, 2020
BioSpace
Capricor Therapeutics, Inc. announced today that the first two patients have been dosed in its Phase 2 study evaluating intravenous infusion of CAP-1002

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.